AmerisourceBergen - ABC Stock Forecast, Price & News

AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. It also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; and packaging solutions to various institutional and retail healthcare providers. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics; and offers data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers. The company's Other segment provides integrated manufacturer services, such as clinical trial support, product post-approval, and commercialization support; specialty transportation and logistics services for the biopharmaceutical industry; and sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in the companion animal and production animal markets, as well as demand-creating sales force services to manufacturers. AmerisourceBergen Corporation was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.

AmerisourceBergen Price Performance

NYSE:ABC traded up $0.45 during trading hours on Monday, reaching $150.95. 45,113 shares of the stock traded hands, compared to its average volume of 1,308,007. The stock has a 50 day simple moving average of $143.29 and a two-hundred day simple moving average of $148.09. AmerisourceBergen has a 1 year low of $113.68 and a 1 year high of $167.19. The company has a debt-to-equity ratio of 8.96, a current ratio of 0.92 and a quick ratio of 0.55. The company has a market cap of $31.62 billion, a price-to-earnings ratio of 17.26, a price-to-earnings-growth ratio of 1.67 and a beta of 0.48.

AmerisourceBergen (NYSE:ABC - Get Rating) last issued its earnings results on Wednesday, August 3rd. The company reported $2.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.56 by $0.06. AmerisourceBergen had a return on equity of 350.60% and a net margin of 0.78%. The business had revenue of $60.06 billion during the quarter, compared to analyst estimates of $59.03 billion. During the same quarter in the prior year, the firm earned $2.16 earnings per share. AmerisourceBergen's revenue for the quarter was up 12.5% on a year-over-year basis. On average, analysts predict that AmerisourceBergen will post 10.99 EPS for the current fiscal year.

AmerisourceBergen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 29th. Stockholders of record on Monday, August 15th will be issued a $0.46 dividend. The ex-dividend date is Friday, August 12th. This represents a $1.84 annualized dividend and a dividend yield of 1.22%. AmerisourceBergen's dividend payout ratio is currently 21.10%.

Analyst Ratings Changes

A number of research firms have weighed in on ABC. StockNews.com raised AmerisourceBergen from a "buy" rating to a "strong-buy" rating in a report on Tuesday, August 9th. Evercore ISI decreased their target price on shares of AmerisourceBergen to $165.00 in a report on Friday, June 3rd. Morgan Stanley cut their price target on shares of AmerisourceBergen from $178.00 to $175.00 and set an "equal weight" rating for the company in a report on Friday, May 27th. Argus boosted their price target on shares of AmerisourceBergen from $160.00 to $170.00 and gave the company a "buy" rating in a research report on Wednesday, July 20th. Finally, UBS Group increased their price objective on AmerisourceBergen from $144.00 to $174.00 and gave the stock a "buy" rating in a research report on Monday, June 13th. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, AmerisourceBergen presently has a consensus rating of "Moderate Buy" and an average target price of $173.45.

Insider Activity

In other AmerisourceBergen news, CEO Steven H. Collis sold 11,480 shares of AmerisourceBergen stock in a transaction that occurred on Tuesday, August 9th. The stock was sold at an average price of $144.25, for a total value of $1,655,990.00. Following the transaction, the chief executive officer now directly owns 205,178 shares of the company's stock, valued at approximately $29,596,926.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders sold 34,440 shares of company stock valued at $4,911,374. Insiders own 28.80% of the company's stock.